Anti-Human CD40L Recombinant Antibody (TAB-027) (CAT#: TAB-027)

Schmidt, Angelika, et al. "Complex human adenoid tissue-based ex vivo culture systems reveal anti-inflammatory drug effects on germinal center T and B cells." EBioMedicine 53 (2020). https://doi.org/10.1016/j.ebiom.2020.102684

This research explores the development of ex vivo culture systems using human adenoid tissue to study germinal center (GC) T follicular helper (Tfh) cells and GC B cells, which are critical for antibody-mediated immunity. The study systematically compared different culture methods, including human lymphoid histoculture (HLH) and human lymphoid aggregate culture (HLAC), to assess their utility for drug testing. The researchers demonstrated that anti-inflammatory drugs affect GC cells in these cultures, particularly showing that CD40L blockade reduces GC B cells and JAK inhibitors downregulate BCL6 expression in both T and B cells. They also optimized an activation-induced marker assay using Pertussis toxin to evaluate T cell responses to vaccination antigens and showed how cytokine signaling influences these responses.
Creative Biolabs provided the anti-CD40L blocking antibody Ruplizumab, which was used to demonstrate the importance of CD40L:CD40 interactions for GC B cell survival. This reagent allowed the researchers to specifically target the CD40L pathway and observe its effects on germinal center maintenance. The application of Ruplizumab helped establish proof-of-concept for the ex vivo platform as a tool for testing immunomodulatory drugs, providing valuable insights into potential therapeutic approaches for autoimmune diseases where dysregulated Tfh responses contribute to pathology.